ReNew Life Formulas, Inc. was founded by President Brenda Watson in 1997. ReNew Life Formulas aims to make a clean sweep of clogged colons and hasten one's pace to the restroom. ReNew Life Formulas company makes and wholesales dietary supplements and therapeutic products for digestive health. Its products CleanseSMART, ParaGONE, CandiGONE, and Liver Detox are a few of the products offered as part of its cleansing and detoxification line. Its digestive support products include fish oils, probiotics, and digestive enzymes. The company also makes products tailored for kids. ReNew Life Formulas sells its products through health food stores and online retailers in the US and Canada.

Momenta Pharmaceuticals was founded in 2001 and is based in Cambridge, Massachusetts. Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs. The company applies its technology for the development of generic versions of complex drug products, as well as for the discovery and development of novel drugs. Its product candidates include M-Enoxaparin, a generic version of Lovenox that is used to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; M356, a technology-enabled generic version of Copaxone, which is used for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; and M118, an anticoagulant. The company also involves in developing generic or biosimilar glycoprotein products. Momenta Pharmaceuticals has collaborations with Sandoz AG and Sandoz Inc. to develop and commercialize injectable enoxaparin. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002.

Mylan Pharmaceuticals isn't a snob when it comes to labels -- the company is the generic research and development, manufacturing, marketing, and distribution division of Mylan. Mylan Pharmaceuticals offers more than 170 generic prescription products developed in-house, as well as nearly 70 products under distribution agreements with other pharmaceutical companies. The company devotes most of its research and development efforts to the development of extended dosages. Its sister company Mylan Technologies develops transdermal and polymer film patches. Its products are sold to pharmaceutical wholesalers, distributors, mail order pharmacies, and drugstore chains.

TECHNE Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. TECHNE Corporation, along with its subsidiaries, is engaged in the development, manufacture, and sale of biotechnology products and hematology calibrators and controls. The Company’s activities are conducted, through its wholly owned subsidiaries, Research and Diagnostic Systems, Inc. (R&D Systems), and BiosPacific, Inc. (BioPacific). The Company distributes the biotechnology products in Europe, through its wholly owned United Kingdom-based subsidiary, R&D Systems Europe Ltd. (R&D Europe). The Company distributes biotechnology products in the People’s Republic of China, through its wholly owned subsidiary, R&D Systems China, Co. Ltd. (R&D China). The Company operates in three business segments: biotechnology, R&D Europe and hematology.

Falcon Pharmaceuticals, Ltd. company specializes in making generic equivalents of ophthalmic drugs that treat a range of eye conditions, as well as otic (ear) and nasal ailments. Its lead product, Timolol GFS, is a generic equivalent of Merck's glaucoma treatment Timoptic-XE gel. Falcon Pharmaceuticals company also offers anti-infective, steroid, anti-viral, anti-allergy, and anesthetic pharmaceutical products without the markup typically associated with brand names. Falcon Pharmaceuticals is a subsidiary of eye care products company Alcon.

MiddleBrook Pharmaceuticals was founded in 1999 and is headquartered in Germantown, Maryland. MiddleBrook Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of anti-infective drug products in the United States. The company develops a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of drugs. Its product portfolio includes MOXATAG tablets for the treatment of pharyngitis and tonsillitis; and KEFLEX capsules for the treatment of skin and skin structure infections and upper respiratory tract infections. MiddleBrook Pharmaceuticals sells its products through specialty pharmaceutical distributors and wholesalers to physicians, hospitals, and pharmacies.

Established in 2004, Merrion operates offices in North Carolina and Ireland. Merrion Pharmaceuticals wants to make complicated drug dosing regimens easier to swallow. A specialty pharmaceutical firm, Merrion develops (independently and in collaboration with other drug companies) oral drugs to replace already-approved injectable-only medicines. Using its patented drug delivery technologies, Merrion's Gastrointestinal Permeation Enhancement Technology (GIPET) improves the absorption of drugs into the blood stream. Its Gastrointestinal Retention System (GIRES) helps the stomach retain drugs, allowing for their extended, controlled release. The company has four candidates in the development pipeline.

EXACT Sciences Corporation company was founded in 1995 and is based in Madison, Wisconsin. Exact Sciences Corporation, a molecular diagnostics company, focuses on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Its non-invasive stool-based DNA (sDNA) screening technology includes proprietary and patented methods that isolate and analyze human DNA present in stool to screen for the presence of colorectal pre-cancer and cancer. The company's principal product includes ColoSure, a non-invasive laboratory developed stool-based DNA testing service for the detection of colorectal cancer in the average-risk population. Exact Sciences Corporation has strategic alliances with Laboratory Corporation of America Holdings, the MAYO Foundation for Medical Education and Research, and Genzyme Corporation.

deCODE genetics, Inc. (deCODE) is a bio-pharmaceutical company developing and marketing products for the treatment, diagnosis, and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in therapeutic areas, and applies its discoveries in human genetics to bring to market deoxyribonucleic acid (DNA)-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. In November 2009, the Company announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware.

Ipsen develops pharmaceutical products that target oncology, endocrinology, and neuromuscular disorders. The group additionally markets products to treat gastroenterology, cardiovascular, and cognitive disorders. Ipsen operates research-and-development (R&D) centers in Paris, Boston, Barcelona, and London, which have churned out more than 20 products to the global therapeutic market. Its R&D efforts focus on peptide engineering, protein engineering, medicinal chemistry, and advanced drug delivery. The company markets its products directly as well as through third parties, and has formed strategic development alliances with the likes of Medicis and Applied Biosystems (now part of Life Technologies Corporation).

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.